Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Epistemonikos ID: 57c33ff3a26c4a0a304a415fbe91ab2067d02245
First added on: May 07, 2024